Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Sciurba (Pittsburgh, United States of America). Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD. 3194

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Silent exacerbations: underreporting of COPD exacerbations in Poland Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition Source: International Congress 2018 – New methods for diagnosing and treating lung diseases Year: 2018 Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Late Breaking Abstract - Azithromycin for acute COPD exacerbations requiring hospitalization – the BACE trial results Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Diagnosis of chronic obstructive pulmonary disease (COPD) exacerbations using a smartphone-based, cough-centred algorithm Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Indacaterol/glycopyrronium versus salmeterol/fluticasone in chronic obstructive pulmonary disease: a meta-analysis on the protection against the risk of exacerbation Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Late Breaking Abstract - Air pollution and IPF acute exacerbation Source: International Congress 2017 – The wide spectrum of ILDs Year: 2017 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014